Last reviewed · How we verify
tapentadol, oxycodone
Tapentadol and oxycodone are opioid analgesics that bind to mu-opioid receptors in the central nervous system to reduce pain perception; tapentadol also inhibits norepinephrine reuptake.
Tapentadol and oxycodone are opioid analgesics used for moderate to severe pain management. Tapentadol has a dual mechanism of action, targeting both μ-opioid receptors and norepinephrine reuptake. Oxycodone primarily acts on μ-opioid receptors. Both drugs have been studied in various pain conditions, including postoperative and neuropathic pain, with tapentadol showing potential advantages in certain settings.
At a glance
| Generic name | tapentadol, oxycodone |
|---|---|
| Also known as | Palexia |
| Sponsor | University Hospital Schleswig-Holstein |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (OPRM1); tapentadol also targets norepinephrine transporter (SLC6A2) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Both drugs are mu-opioid receptor agonists that work by binding to opioid receptors in the brain and spinal cord, thereby decreasing pain signal transmission. Tapentadol has a dual mechanism, combining mu-opioid agonism with norepinephrine reuptake inhibition, which may enhance analgesia through multiple pathways. Oxycodone acts primarily through mu-opioid receptor activation.
Approved indications
- Moderate to severe acute pain
- Moderate to severe chronic pain
Common side effects
- Nausea
- Dizziness
- Constipation
- Somnolence
- Vomiting
- Headache
- Respiratory depression
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tapentadol, oxycodone CI brief — competitive landscape report
- tapentadol, oxycodone updates RSS · CI watch RSS
- University Hospital Schleswig-Holstein portfolio CI